Targeting oncogenic ALK: a promising strategy for cancer treatment.

doi:10.1158/1535-7163.MCT-10-0615

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Targeting oncogenic ALK: a promising strategy for cancer treatment.

Molecular cancer therapeutics - 1 Apr 2011

Grande Enrique, Bolós María-Victoria, Arriola Edurne

Abstract excerpt

Recently, the anaplastic lymphoma kinase (ALK) has been found to be altered in several solid and hematologic tumors. Novel drugs targeting this tyrosine kinase receptor are under development, and early clinical trials are showing promising activity in non-small cell lung cancer patients with ALK+ tumors. Here, we review the structure and function of the ALK receptor, the mechanisms associated with its...

Topics

Anaplastic Lymphoma Kinase
Antineoplastic Agents
Enzyme Inhibitors
Gene Amplification
Humans
Mutation
Neoplasms
Oncogene Proteins, Fusion
Protein-Tyrosine Kinases
Pyrimidines
Receptor Protein-Tyrosine Kinases

Source

Open in PubMed

Identifiers

PMID: 21474455
DOI: 10.1158/1535-7163.MCT-10-0615

Genes

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics